文献速递心脑血管急症重症综合管理与镇静镇痛

心房颤动导管消融术后长期停用抗凝:ALONE-AF随机临床试验

Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01
一句话结论无房性心律失常复发者消融后停用口服抗凝药,2年卒中、体循环栓塞及大出血复合终点低于继续直接口服抗凝药。

ALONE-AF为韩国18家医院开展的随机临床试验,纳入840例19-80岁、至少1项非性别相关卒中危险因素、房颤导管消融后至少1年无房性心律失常复发的患者,1:1随机分为停用口服抗凝药组(n=417)与继续直接口服抗凝药组(n=423)。2年时主要复合终点(卒中、体循环栓塞及大出血)在停药组发生1例(0.3%),继续组8例(2.2%),绝对差异-1.9个百分点(95%CI -3.5至-0.3;P=.02)。2年缺血性卒中累积发生率停药组0.3% vs 继续组0.8%(绝对差异-0.5个百分点,95%CI -1.6至0.6);大出血停药组0例 vs 继续组5例(1.4%)(绝对差异-1.4个百分点,95%CI -2.6至-0.2)。作者结论认为,在此类无房性心律失常复发患者中,停用口服抗凝药较继续直接口服抗凝药降低了复合终点风险。

要点

  • 纳入标准:房颤导管消融后至少1年无房性心律失常复发、至少1项非性别相关卒中危险因素(CHA2DS2-VASc评分)、年龄19-80岁。
  • 2年主要复合终点(卒中、体循环栓塞、大出血):停药组1例(0.3%)vs 继续组8例(2.2%),绝对差异-1.9个百分点(95%CI -3.5至-0.3;P=.02)。
  • 2年大出血:停药组0例 vs 继续组5例(1.4%),绝对差异-1.4个百分点(95%CI -2.6至-0.2)。
  • 2年缺血性卒中累积发生率:停药组0.3% vs 继续组0.8%,绝对差异-0.5个百分点(95%CI -1.6至0.6),未达统计学显著。
  • 研究人群平均年龄64岁(SD 8),女性24.9%,平均CHA2DS2-VASc评分2.1(SD 1.0),67.6%为阵发性房颤。

适用人群与场景

  • 成人患者,年龄19-80岁,房颤导管消融后至少1年无房性心律失常复发记录,且至少1项非性别相关卒中危险因素(依据CHA2DS2-VASc评分)。
  • 研究在韩国18家医院入组,入组时间2020年7月28日至2023年3月9日,最终随访日期2025年6月4日。
  • 研究人群平均年龄64岁(SD 8),女性24.9%,平均CHA2DS2-VASc评分2.1(SD 1.0),67.6%为阵发性房颤。

诊断标准与关键阈值

  • 卒中危险因素采用CHA2DS2-VASc评分(范围0-9)评估,评分项目包括充血性心力衰竭、高血压、年龄≥75岁、糖尿病、卒中或短暂性脑缺血发作、血管疾病、年龄65-74岁及性别类别。
  • 入组条件为房颤导管消融后至少1年无房性心律失常复发记录。

处置流程与药物剂量

  • 符合条件的患者随机1:1分配至停用口服抗凝药组(n=417)或继续口服抗凝药组(继续使用直接口服抗凝药,n=423)。

研究设计与关键结果

  • 研究类型:随机临床试验,纳入840例成人患者,在韩国18家医院开展。
  • 主要终点为2年内卒中、体循环栓塞及大出血复合终点的首次发生;2年时停药组发生1例(0.3%)vs 继续组8例(2.2%),绝对差异-1.9个百分点(95%CI -3.5至-0.3;P=.02)。
  • 次要终点:2年缺血性卒中累积发生率停药组0.3% vs 继续组0.8%,绝对差异-0.5个百分点(95%CI -1.6至0.6)。
  • 次要终点:大出血停药组0例 vs 继续组5例(1.4%),绝对差异-1.4个百分点(95%CI -2.6至-0.2)。
  • 作者结论:在房颤导管消融后无房性心律失常复发记录的患者中,停用口服抗凝药较继续直接口服抗凝药降低了卒中、体循环栓塞及大出血复合终点风险。

证据类型、等级与局限

  • 证据类型:随机临床试验(RCT)。
  • 试验注册:ClinicalTrials.gov标识NCT04432220。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于房颤导管消融后至少1年无房性心律失常复发、存在至少1项非性别相关卒中危险因素且CHA2DS2-VASc评分均值约2.1的成人患者,本研究显示停用口服抗凝药(n=417)较继续直接口服抗凝药(n=423)2年主要复合终点更低(0.3% vs 2.2%)。
  • 研究仅纳入19-80岁、消融后至少1年无复发且至少1项非性别相关卒中危险因素者,不适用于此范围外患者。

指南或共识出处

  • ALONE-AF随机临床试验(ClinicalTrials.gov NCT04432220),发表于JAMA。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Data from randomized clinical trials on a long-term anticoagulation strategy for patients after catheter-based ablation for atrial fibrillation (AF) are lacking.

OBJECTIVE: To evaluate whether discontinuing oral anticoagulant therapy provides superior clinical outcomes compared with continuing oral anticoagulant therapy in patients without documented atrial arrhythmia recurrence after catheter ablation for AF.

DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial including 840 adult patients (aged 19-80 years) who were enrolled and randomized from July 28, 2020, to March 9, 2023, at 18 hospitals in South Korea. Enrolled patients had at least 1 non-sex-related stroke risk factor (determined using the CHA2DS2-VASc score [range, 0-9]) and no documented recurrence of atrial arrhythmia for at least 1 year after catheter ablation for AF. The CHA2DS2-VASc score is used as an assessment of stroke risk among patients with AF (calculated using point values for congestive heart failure, hypertension, ≥75 years of age, diabetes, stroke or transient ischemic attack, vascular disease, between 65 and 74 years of age, and sex category). The date of final follow-up was June 4, 2025.

INTERVENTIONS: The patients were randomly assigned in a 1:1 ratio to discontinue oral anticoagulant therapy (n = 417) or continue oral anticoagulant therapy (with direct oral anticoagulants; n = 423).

MAIN OUTCOMES AND MEASURES: The primary outcome was the first occurrence of a composite of stroke, systemic embolism, and major bleeding at 2 years. Individual components of the primary outcome (such as ischemic stroke and major bleeding) were assessed as secondary outcomes.

RESULTS: Of the 840 adults randomized, the mean age was 64 (SD, 8) years, 24.9% were women, the mean CHA2DS2-VASc score was 2.1 (SD, 1.0), and 67.6% had paroxysmal AF. At 2 years, the primary outcome occurred in 1 patient (0.3%) in the discontinue oral anticoagulant therapy group vs 8 patients (2.2%) in the continue oral anticoagulant therapy group (absolute difference, -1.9 percentage points [95% CI, -3.5 to -0.3]; P = .02). The 2-year cumulative incidence of ischemic stroke was 0.3% in the discontinue oral anticoagulant therapy group vs 0.8% in the continue oral anticoagulant therapy group (absolute difference, -0.5 percentage points [95% CI, -1.6 to 0.6]). Major bleeding occurred in 0 patients in the discontinue oral anticoagulant therapy group vs 5 patients (1.4%) in the continue oral anticoagulant therapy group (absolute difference, -1.4 percentage points [95% CI, -2.6 to -0.2]).

CONCLUSIONS AND RELEVANCE: Among patients without documented atrial arrhythmia recurrence after catheter ablation for AF, discontinuing oral anticoagulant therapy resulted in a lower risk for the composite outcome of stroke, systemic embolism, and major bleeding vs continuing direct oral anticoagulant therapy.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04432220.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Kim D, Shim J, Choi EK, et al. Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial. JAMA. 2025. PMID: 40886309. doi:10.1001/jama.2025.14679

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。